Skip to content

D60.8

Billable

Other acquired pure red cell aplasias

Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)

Is D60.8 an HCC code?

Yes. D60.8 maps to Hemolytic and Aplastic Anemias under the CMS-HCC V28 risk adjustment model (and Severe Hematological Disorders under V24).

HCC Category Mapping

V28HCC 109Hemolytic and Aplastic Anemias
0.291
V24HCC 46Severe Hematological Disorders
0.666
ESRDHCC 46Severe Hematological Disorders
0.000
RxHCCHCC 96Hemolytic and Aplastic Anemias
0.000

RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.

MEAT Criteria for D60.8

For D60.8 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.

  • MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
  • EEvaluate: test results, medication response, or physical findings reviewed by the provider
  • AAssess: explicit mention in the assessment or plan with acknowledgment of status
  • TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis

Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed D60.8 during that encounter — not just copy-forwarded from a problem list.

What This Code Means

D60.8 is the ICD-10-CM diagnosis code for other acquired pure red cell aplasias. A rare condition where the bone marrow fails to produce red blood cells due to causes other than those specified in other pure red cell aplasia codes. D60.8 sits in the ICD-10-CM chapter for diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (d50-d89), within the section covering aplastic and other anemias and other bone marrow failure syndromes (d60-d64).

Under the CMS-HCC V28 risk adjustment model, D60.8 maps to Hemolytic and Aplastic Anemias (HCC 109) with a community, non-dual, aged base RAF weight of 0.291. Under the older CMS-HCC V24 model, D60.8 maps to Severe Hematological Disorders (HCC 46) with a community, non-dual, aged base RAF weight of 0.666. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.

Use this code when documentation describes a specific etiology that doesn't fit D60.0 or D60.1; document the underlying cause clearly. Because D60.8 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.

HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for D60.8 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.

Coding Tips

  • Use this code when documentation describes a specific etiology that doesn't fit D60.0 or D60.1; document the underlying cause clearly
  • Review the medical record for any identifiable triggers or associated conditions

Clinical Significance

Other acquired pure red cell aplasias captures rare forms of selective erythroid failure not classified as chronic or transient, including pure red cell aplasia associated with specific autoimmune mechanisms (such as anti-erythropoietin antibodies), pregnancy-related pure red cell aplasia, and aplasia secondary to specific medications where the mechanism is distinct from transient suppression. These conditions share the hallmark of isolated erythroid failure with preserved myeloid and megakaryocyte production but have unique etiologies requiring targeted management.

Documentation Requirements

  • Document the specific cause or subtype of pure red cell aplasia that distinguishes it from chronic (D60.0) or transient (D60.1) forms.
  • Record bone marrow biopsy showing selective erythroid hypoplasia.
  • Include hemoglobin, reticulocyte count, and documentation that white blood cell and platelet counts are preserved.
  • Note any identified causative factors such as anti-erythropoietin antibodies, specific medications, or pregnancy.
  • Document treatment approach and response.

Commonly Confused Codes

  • D60.0 (Chronic acquired pure red cell aplasia) is for long-term persistent forms.
  • D60.1 (Transient acquired pure red cell aplasia) is for self-resolving episodes.
  • D60.9 (Acquired pure red cell aplasia, unspecified) does not specify the subtype.
  • D61.09 (Other constitutional aplastic anemia) is for inherited, not acquired, conditions.
  • D61.1 (Drug-induced aplastic anemia) affects all cell lines, not just erythroid.

Code Hierarchy

Open D60.8 in the Interactive Encoder

See full code details, AI coding tips, HCC mappings, and related codes in our interactive encoder. Start your 14-day Pro trial — no credit card required.